AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21733046 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder letters for missed follow-up visits (Group 3)
Number of subjects: 221
Study 21733046 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 1) with no additional intervention
Number of subjects: 221
Study 19592595 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide 200 microg
Number of subjects: 16
Study 19592595 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide 400 microg
Number of subjects: 16
Study 19592595 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide 800 microg
Number of subjects: 16
Study 19592595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 17229426 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg/day
Number of subjects: 871
Study 17229426 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 80 mg/day
Number of subjects: 871
Study 16104943 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori eradication (active group, n = 9)
Number of subjects: 56
Study 16104943 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group, n = 11)
Number of subjects: 56
Study 16104943 — intervention group
Group type: EXPERIMENTAL
Intervention: Active eradication (blind or open)
Number of subjects: 56
Study 12924797 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine group (received intramuscular injection with purified trivalent split‐virus vaccine)
Number of subjects: 125
Study 12924797 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (received intramuscular injection with vit B1)
Number of subjects: 125
Study 12924797 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine group (mild COPD)
Number of subjects: 125
Study 12924797 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (mild COPD)
Number of subjects: 125
Study 12924797 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine group (moderate COPD)
Number of subjects: 125
Study 12924797 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (moderate COPD)
Number of subjects: 125
Study 12924797 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine group (severe COPD)
Number of subjects: 125
Study 12924797 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (severe COPD)
Number of subjects: 125
Study 12924797 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine group (all COPD patients)
Number of subjects: 125
Study 12924797 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine group (patients with severe airflow obstruction)
Number of subjects: 125
Study 10396014 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis with active suggestions of improvement
Number of subjects: 11
Study 10396014 — intervention group
Group type: COMPARATOR
Intervention: Neutral hypnosis with no mention of disease process
Number of subjects: 11
Study 8634222 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine (administered over a 4-8 week period)
Number of subjects: 40
Study 1962780 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (cisplatin and vinblastine) followed by radiotherapy
Number of subjects: 180
Study 1962780 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 180
Study 6115521 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg metoprolol (acute beta 1-adrenergic blockade)
Number of subjects: 14
Study 29534456 — intervention group
Group type: EXPERIMENTAL
Intervention: Insect protein isolate
Number of subjects: 18
Study 29534456 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric carbohydrate supplementation
Number of subjects: 18
Study 27089159 — intervention group
Group type: EXPERIMENTAL
Intervention: CT+Memory Support
Number of subjects: 48
Study 27089159 — intervention group
Group type: COMPARATOR
Intervention: CT-as-usual
Number of subjects: 48
Study 23928139 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced FIESTA
Number of subjects: 29
Study 23928139 — intervention group
Group type: COMPARATOR
Intervention: Contrast-enhanced T1WI
Number of subjects: 29
Study 23928139 — intervention group
Group type: COMPARATOR
Intervention: Contrast-enhanced T2WI
Number of subjects: 29
Study 23928139 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid-type adenomas
Number of subjects: 29
Study 22796247 — intervention group
Group type: EXPERIMENTAL
Intervention: FF Rotadisk 100 μg once daily in the morning
Number of subjects: 575
Study 22796247 — intervention group
Group type: EXPERIMENTAL
Intervention: FF Rotadisk 100 μg once daily in the evening
Number of subjects: 575
Study 22796247 — intervention group
Group type: EXPERIMENTAL
Intervention: FF Rotadisk 250 μg once daily in the evening
Number of subjects: 575
Study 22796247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 575
Study 20090429 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 0
Study 18558697 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry Juice (CJ)
Number of subjects: 10
Study 18558697 — intervention group
Group type: COMPARATOR
Intervention: High Fructose Corn Syrup (HFCS)
Number of subjects: 10
Study 16187917 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of octreotide-LAR every 4 weeks for 16 weeks
Number of subjects: 26
Study 16187917 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 12117048 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibreoptic bronchoscopy (FOB) with local Lignocaine anaesthesia
Number of subjects: 57
Study 10412894 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioxane (dexrazoxane hydrochloride salt)
Number of subjects: 15
Study 10412894 — intervention group
Group type: COMPARATOR
Intervention: ICRF‐187 (dexrazoxane base)
Number of subjects: 15
Study 7585851 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxatidine (150 mg)
Number of subjects: 620
Study 7585851 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (300 mg)
Number of subjects: 620
Study 2223741 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein diet enriched with fat (HP/F)
Number of subjects: 0
Study 2223741 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein diet enriched with carbohydrate (HP/C)
Number of subjects: 0
Study 2223741 — intervention group
Group type: EXPERIMENTAL
Intervention: Low protein diet enriched with fat (LP/F)
Number of subjects: 0
Study 2223741 — intervention group
Group type: EXPERIMENTAL
Intervention: Low protein diet enriched with carbohydrate (LP/C)
Number of subjects: 0
Study 2223741 — intervention group
Group type: EXPERIMENTAL
Intervention: Low protein diets (LP)
Number of subjects: 0
Study 7384769 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose syrup ingestion in the morning
Number of subjects: 57
Study 7384769 — intervention group
Group type: COMPARATOR
Intervention: High energy intake (mean 15 MJ or 3,600 kcal)
Number of subjects: 57
Study 7384769 — intervention group
Group type: COMPARATOR
Intervention: Alcohol intake (1 to 2 MJ or 240 to 480 kcal)
Number of subjects: 57
Study 31373978 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional crunch
Number of subjects: 15
Study 31373978 — intervention group
Group type: COMPARATOR
Intervention: 5-minute Shaper device
Number of subjects: 15
Study 31561490 — intervention group
Group type: EXPERIMENTAL
Intervention: Western diet high-fat (WD) with moderate walking (4.6 ± 0.1 km/h)
Number of subjects: 26
Study 31561490 — intervention group
Group type: COMPARATOR
Intervention: Western diet high-fat (WD) with rest
Number of subjects: 26
Study 31561490 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean-type diet (MD) with moderate walking (4.6 ± 0.1 km/h)
Number of subjects: 26
Study 31561490 — intervention group
Group type: COMPARATOR
Intervention: Mediterranean-type diet (MD) with rest
Number of subjects: 26
Study 31561490 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 26
Study 28504033 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage chemotherapy (dexamethasone, cytarabine, cisplatin)
Number of subjects: 59
Study 28504033 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplant
Number of subjects: 59
Study 28504033 — intervention group
Group type: COMPARATOR
Intervention: Comparison to B-cell lymphoma
Number of subjects: 59
Study 25844857 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-wave diathermy (SWD) heat treatment for 40 minutes
Number of subjects: 15
Study 25844857 — intervention group
Group type: COMPARATOR
Intervention: Control group (rest without SWD)
Number of subjects: 15
Study 23685295 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate invasive strategy (angiography and revascularisation <12 hr)
Number of subjects: 542
Study 23685295 — intervention group
Group type: COMPARATOR
Intervention: Delayed invasive strategy (>48 hr after randomisation)
Number of subjects: 542
Study 23685295 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate invasive strategy
Number of subjects: 542
Study 23685295 — intervention group
Group type: COMPARATOR
Intervention: Delayed invasive strategy
Number of subjects: 542
Study 21530722 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week program of combined exercise and dietary advice
Number of subjects: 18
Study 21530722 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 18
Study 19842561 — intervention group
Group type: EXPERIMENTAL
Intervention: Dressing composed of alginate + cotton pad
Number of subjects: 186
Study 19842561 — intervention group
Group type: EXPERIMENTAL
Intervention: Dressing composed of vaseline gauze + cotton pad
Number of subjects: 186
Study 19842561 — intervention group
Group type: EXPERIMENTAL
Intervention: Dressing composed of alginate + foam dressing
Number of subjects: 186
Study 19842561 — intervention group
Group type: EXPERIMENTAL
Intervention: Dressing composed of vaseline gauze + foam dressing
Number of subjects: 186
Study 16676705 — intervention group
Group type: EXPERIMENTAL
Intervention: Chocolate milk
Number of subjects: 9
Study 16676705 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid replacement drink (FR)
Number of subjects: 9
Study 16676705 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate replacement drink (CR)
Number of subjects: 9
Study 14670772 — intervention group
Group type: EXPERIMENTAL
Intervention: Constipated children (30)
Number of subjects: 90
Study 14670772 — intervention group
Group type: EXPERIMENTAL
Intervention: First degree relatives of constipated children (30)
Number of subjects: 90
Study 14670772 — intervention group
Group type: COMPARATOR
Intervention: Control children (30)
Number of subjects: 90
Study 14670772 — intervention group
Group type: COMPARATOR
Intervention: First degree relatives of control children (30)
Number of subjects: 90
Study 14670772 — intervention group
Group type: EXPERIMENTAL
Intervention: Relatives of arch positive children (6)
Number of subjects: 90
Study 14670772 — intervention group
Group type: EXPERIMENTAL
Intervention: Relatives of arch negative children (54)
Number of subjects: 90
Study 10703777 — intervention group
Group type: EXPERIMENTAL
Intervention: IV tPA therapy
Number of subjects: 3948
Study 10703777 — intervention group
Group type: COMPARATOR
Intervention: Not receiving tPA
Number of subjects: 3948
Study 8792483 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-component DTaP vaccine
Number of subjects: 158
Study 8792483 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-component DTaP vaccine
Number of subjects: 158
Study 8792483 — intervention group
Group type: COMPARATOR
Intervention: DTwP vaccine
Number of subjects: 158
Study 1514322 — intervention group
Group type: EXPERIMENTAL
Intervention: Wake time between 8.00 to 11.00 a.m.
Number of subjects: 573
Study 1514322 — intervention group
Group type: EXPERIMENTAL
Intervention: Wake time during the initial 3 hours after awakening
Number of subjects: 573
Study 1514322 — intervention group
Group type: EXPERIMENTAL
Intervention: ADP threshold concentration in 10 patients with CAD
Number of subjects: 573
Study 1514322 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine threshold concentration in 10 patients with CAD
Number of subjects: 573
Study 6335343 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol group (last metoprolol dose given 1.5 h before the anaesthesia)
Number of subjects: 20
Study 6335343 — intervention group
Group type: COMPARATOR
Intervention: Control group (last metoprolol dose 12 h before the anaesthesia)
Number of subjects: 20
Study 6335343 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 6335343 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol group
Number of subjects: 20
Study 31084656 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education programme (NEP) for 12 weeks
Number of subjects: 200
Study 31084656 — intervention group
Group type: COMPARATOR
Intervention: Brochure on nutrition guidelines for ALH (Control)
Number of subjects: 200
Study 28935614 — intervention group
Group type: EXPERIMENTAL
Intervention: Air-filtration intervention
Number of subjects: 0
Study 28935614 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved-technology woodstove intervention
Number of subjects: 0
Study 28935614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26032211 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 IU of intranasal salmon calcitonin daily for 3 months
Number of subjects: 41
Study 26032211 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 24062391 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab plus CHOP
Number of subjects: 292
Study 24062391 — intervention group
Group type: COMPARATOR
Intervention: CHOP without Rituximab
Number of subjects: 292
Study 24062391 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy to sites of skeletal involvement
Number of subjects: 292
Study 24062391 — intervention group
Group type: COMPARATOR
Intervention: Rituximab (MInT and RICOVER-60 studies)
Number of subjects: 292
Study 21804061 — intervention group
Group type: EXPERIMENTAL
Intervention: Lozenges containing anti-CA-gtf IgY
Number of subjects: 0
Study 21804061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21804061 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 19390525 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% energy restriction (ER)
Number of subjects: 38
Study 19390525 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% energy restriction (ER)
Number of subjects: 38
Study 16650295 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (100 mg tds for 3 months) with ofloxacin (200 mg tds for 3 weeks)
Number of subjects: 56
Study 16650295 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets with ofloxacin (200 mg tds for 3 weeks)
Number of subjects: 56
Study 16650295 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 56
Study 16650295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 14647985 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphoscintigraphy with nanocolloids (NC) injected in a peritumoral site (group I)
Number of subjects: 227
Study 14647985 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphoscintigraphy with nanocolloids (NC) injected in a subdermal site (group II)
Number of subjects: 227
Study 14647985 — intervention group
Group type: EXPERIMENTAL
Intervention: Sole injection of NC into the lesion (group III)
Number of subjects: 227
Study 14647985 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ROLL procedure with direct injection of MAA into the lesion and lymphoscintigraphy with subdermal injection of radiocolloids
Number of subjects: 227
Study 14647985 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative examination of SNs
Number of subjects: 227
Study 11707007 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate (400 mg/d cyclically for 14 days with 76-day intervals, plus calcium and vitamin D)
Number of subjects: 99
Study 11707007 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg/d daily)
Number of subjects: 99
Study 11707007 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate with HRT
Number of subjects: 99
Study 11707007 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate without HRT
Number of subjects: 99
Study 11707007 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 99
Study 10346656 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive-competition program (multicomponent program + cash incentives + team competition)
Number of subjects: 185
Study 10346656 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent program (self-help package + telephone counseling + other elements)
Number of subjects: 185
Study 10346656 — intervention group
Group type: COMPARATOR
Intervention: Traditional program (standard smoking cessation program)
Number of subjects: 185
Study 10346656 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive-competition program
Number of subjects: 185
Study 10346656 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent program
Number of subjects: 185
Study 10346656 — intervention group
Group type: COMPARATOR
Intervention: Traditional program
Number of subjects: 185
Study 8006837 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial crowns with sintered noble metal margins (Degusint U)
Number of subjects: 12
Study 8006837 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial crowns with cast noble metal margins (Degudent U)
Number of subjects: 12
Study 8006837 — intervention group
Group type: COMPARATOR
Intervention: Adjacent natural teeth
Number of subjects: 12
Study 2521086 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine
Number of subjects: 8
Study 2521086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1096666 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hyoscine butylbromide (Buscopan)
Number of subjects: 0
Study 1096666 — intervention group
Group type: COMPARATOR
Intervention: Atropine sulphate
Number of subjects: 0
Study 27503036 — intervention group
Group type: EXPERIMENTAL
Intervention: MRA + forum
Number of subjects: 142
Study 27503036 — intervention group
Group type: COMPARATOR
Intervention: MRA alone
Number of subjects: 142
Study 27503036 — intervention group
Group type: COMPARATOR
Intervention: Forum access alone
Number of subjects: 142
Study 26223781 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted brief motivational intervention (CA-BMI)
Number of subjects: 300
Study 26223781 — intervention group
Group type: COMPARATOR
Intervention: Non-adapted brief motivational intervention (NA-BMI)
Number of subjects: 300
Study 24160205 — intervention group
Group type: COMPARATOR
Intervention: No liquids
Number of subjects: 14
Study 24160205 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain water
Number of subjects: 14
Study 24160205 — intervention group
Group type: EXPERIMENTAL
Intervention: Sports drinks (SD)
Number of subjects: 14
Study 21471783 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal extraperitoneal block (AEP)
Number of subjects: 0
Study 21471783 — intervention group
Group type: COMPARATOR
Intervention: Patient controlled analgesia (PCA)
Number of subjects: 0
Study 18373526 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil 10 mg (titrated to 5 mg or 20 mg based on efficacy and safety)
Number of subjects: 395
Study 18373526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 395
Study 16434427 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective ET‐A antagonist, BQ‐123 (n = 8) at 1000 and 3000 nmol/min
Number of subjects: 16
Study 16434427 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective ET‐B antagonist, BQ‐788 (n = 8) at 100 and 300 nmol/min
Number of subjects: 16
Study 16434427 — intervention group
Group type: COMPARATOR
Intervention: Matched saline placebo (n = 8)
Number of subjects: 16
Study 12432293 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.3% nifedipine and 1.5% lidocaine ointment every 12 hours for 6 weeks
Number of subjects: 110
Study 12432293 — intervention group
Group type: COMPARATOR
Intervention: Topical 1.5% lidocaine and 1% hydrocortisone acetate ointment
Number of subjects: 110
Study 9872815 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapleural urokinase (UK)
Number of subjects: 31
Study 9872815 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 31
Study 7726809 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment for social phobia (used for both refusers and excluded subjects)
Number of subjects: 0
Study 7726809 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment for social phobia (for acceptors)
Number of subjects: 0
Study 2193461 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide plus leuprolide (LHRH-agonist)
Number of subjects: 0
Study 2193461 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide monotherapy
Number of subjects: 0
Study 2193461 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide in combination with LHRH-agonist
Number of subjects: 0
Study 2193461 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide plus flutamide
Number of subjects: 0
Study 6988951 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline prophylaxis
Number of subjects: 100
Study 6988951 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylaxis)
Number of subjects: 100
Study 6432398 — intervention group
Group type: EXPERIMENTAL
Intervention: DL-Threo-3,4-dihydroxyphenylserine (DL-DOPS) 600 mg
Number of subjects: 6
Study 6432398 — intervention group
Group type: EXPERIMENTAL
Intervention: DL-Threo-3,4-dihydroxyphenylserine (DL-DOPS) 800 mg
Number of subjects: 6
Study 6432398 — intervention group
Group type: COMPARATOR
Intervention: DL-Threo-3,4-dihydroxyphenylserine (DL-DOPS)
Number of subjects: 6
Study 6432398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 30580082 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine treatment (6-8 weeks)
Number of subjects: 0
Study 30580082 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (6-8 weeks)
Number of subjects: 0
Study 29319461 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 32
Study 29319461 — intervention group
Group type: COMPARATOR
Intervention: Waking state (Control)
Number of subjects: 32
Study 26555870 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 minutes of active air-forced warming after EDA and before induction of general anaesthesia (n=33)
Number of subjects: 99